Adverse events1,352

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,352

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	ABDOMINAL INFECTION	Infections and infestations	Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC	1	128	1
other	ABDOMINAL INFECTION	Infections and infestations	Cohort A Part B: Nivolumab/Ipilimumab in Clear Cell RCC	0	40	0
other	ABDOMINAL INFECTION	Infections and infestations	Cohort B Part A: Nivolumab Monotherapy in Non-clear Cell RCC	0	35	0
other	ABDOMINAL INFECTION	Infections and infestations	Cohort B Part B: Nivolumab/Ipilimumab in Non-clear Cell RCC	0	17	0
other	ABDOMINAL PAIN	Gastrointestinal disorders	Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC	19	128	23
other	ABDOMINAL PAIN	Gastrointestinal disorders	Cohort A Part B: Nivolumab/Ipilimumab in Clear Cell RCC	5	40	5
other	ABDOMINAL PAIN	Gastrointestinal disorders	Cohort B Part A: Nivolumab Monotherapy in Non-clear Cell RCC	6	35	8
other	ABDOMINAL PAIN	Gastrointestinal disorders	Cohort B Part B: Nivolumab/Ipilimumab in Non-clear Cell RCC	4	17	7
other	ACUTE KIDNEY INJURY	Renal and urinary disorders	Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC	2	128	2
other	ACUTE KIDNEY INJURY	Renal and urinary disorders	Cohort A Part B: Nivolumab/Ipilimumab in Clear Cell RCC	2	40	2
other	ACUTE KIDNEY INJURY	Renal and urinary disorders	Cohort B Part A: Nivolumab Monotherapy in Non-clear Cell RCC	0	35	0
other	ACUTE KIDNEY INJURY	Renal and urinary disorders	Cohort B Part B: Nivolumab/Ipilimumab in Non-clear Cell RCC	0	17	0
other	ADRENAL INSUFFICIENCY	Endocrine disorders	Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC	3	128	3
other	ADRENAL INSUFFICIENCY	Endocrine disorders	Cohort A Part B: Nivolumab/Ipilimumab in Clear Cell RCC	3	40	4
other	ADRENAL INSUFFICIENCY	Endocrine disorders	Cohort B Part A: Nivolumab Monotherapy in Non-clear Cell RCC	0	35	0
other	ADRENAL INSUFFICIENCY	Endocrine disorders	Cohort B Part B: Nivolumab/Ipilimumab in Non-clear Cell RCC	0	17	0
other	AGITATION	Psychiatric disorders	Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC	3	128	5
other	AGITATION	Psychiatric disorders	Cohort A Part B: Nivolumab/Ipilimumab in Clear Cell RCC	0	40	0
other	AGITATION	Psychiatric disorders	Cohort B Part A: Nivolumab Monotherapy in Non-clear Cell RCC	0	35	0
other	AGITATION	Psychiatric disorders	Cohort B Part B: Nivolumab/Ipilimumab in Non-clear Cell RCC	0	17	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03117309/events

API reference For AI assistants

Adverse events1,352

Sources 3

Read this list from software.